help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quinkler, M.
Right arrow Articles by Diederich, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quinkler, M.
Right arrow Articles by Diederich, S.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 6 2803-2809
Copyright © 2003 by The Endocrine Society

The Human Kidney Is a Progesterone-Metabolizing and Androgen-Producing Organ

M. Quinkler, C. Bumke-Vogt, B. Meyer, V. Bähr, W. Oelkers and S. Diederich

Department of Endocrinology, Klinikum Benjamin Franklin, Free University, 12200 Berlin, Germany

Address all correspondence and requests for reprints to: Dr. Marcus Quinkler, Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom B15 2TH. E-mail: m.o.quinkler{at}bham.ac.uk.

Progesterone (P) is a potent antagonist of the human mineralocorticoid receptor (MR) in vitro. We have previously demonstrated effective downstream metabolism of P in the kidney. This mechanism potentially protects the MR from P action. Here, we have investigated the expression and functional activity of steroidogenic enzymes in human kidney. RT-PCR analysis demonstrated the expression of 5{alpha}-reductase type 1, 5ß-reductase, aldo-keto-reductase (AKR) 1C1, AKR1C2, AKR1C3, 3ß-hydroxysteroid dehydrogenase (3ß-HSD) type 2, and 17{alpha}-hydroxylase/17,20-lyase (P450c17). The presence of 3ß-HSD type 2 and P450c17 indicated that conversion of pregnenolone to dehydroepiandrosterone (DHEA) and to androstenedione may take place effectively in kidney. To investigate this further, we incubated kidney subcellular fractions with radiolabeled pregnenolone. This resulted in efficient formation of DHEA from pregnenolone, indicating both 17{alpha}-hydroxylase and 17,20-lyase activities exerted by P450c17. Radiolabeled DHEA was converted via androstenedione, androstenediol, and testosterone, indicating both 3ß-HSD type 2 activity and 17ß-HSD activity. In addition, the conversion of testosterone to 5{alpha}-dihydrotestosterone was detectable, indicating 5{alpha}-reductase activity. In conclusion, we verified the expression and functional activity of several enzymes involved in downstream metabolism of P and androgen synthesis in human kidney. These findings may be critical to the understanding of water balance during the menstrual cycle and pregnancy and of sex differences in hypertension.

This work was supported by Research Grant DI 741/1-3 from the Deutsche Forschungsgemeinschaft (to S.D.) and Deutsche Forschungsgemeinschaft Postdoctoral Research Fellowship Grant QU142/1-1 (to M.Q.).

Abbreviations: AKR, Aldo-keto-reductase; 20{alpha}-DH-P, 20{alpha}-dihydroprogesterone; DHEA, dehydroepiandrosterone; DH-T, dihydrotestosterone; 3{alpha}-diol, 3{alpha}-androstanediol; 4-dione, androstenedione; 3ß-HSD, 3ß-hydroxysteroid dehydrogenase; MR, mineralocorticoid receptor; 17{alpha}-OH-P, 17{alpha}-hydroxyprogesterone; 17{alpha}-OH-Preg, 17{alpha}-hydroxypregnenolone; P, progesterone; P450c17, 17{alpha}-hydroxylase/17,20-lyase; Preg, pregnenolone; T, testosterone; 3ß,5{alpha}-TH-P, 5{alpha}-pregnan-3ß-ol-20-one; TLC, thin layer chromatography; Vmax, maximal reaction velocity.




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Sun, K. Devish, W. J. Langer, P. K. Carmines, and P. H. Lane
Testosterone treatment promotes tubular damage in experimental diabetes in prepubertal rats
Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1681 - F1690.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. F. Reckelhoff, L. L. Yanes, R. Iliescu, L. A. Fortepiani, and J. P. Granger
Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease
Am J Physiol Renal Physiol, November 1, 2005; 289(5): F941 - F948.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Quinkler, I. J. Bujalska, K. Kaur, C. U. Onyimba, S. Buhner, B. Allolio, S. V. Hughes, M. Hewison, and P. M. Stewart
Androgen Receptor-Mediated Regulation of the {alpha}-Subunit of the Epithelial Sodium Channel in Human Kidney
Hypertension, October 1, 2005; 46(4): 787 - 798.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. K. Bledsoe, K. P. Madauss, J. A. Holt, C. J. Apolito, M. H. Lambert, K. H. Pearce, T. B. Stanley, E. L. Stewart, R. P. Trump, T. M. Willson, et al.
A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor
J. Biol. Chem., September 2, 2005; 280(35): 31283 - 31293.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Liu, H. Ishikawa, F.-J. Li, Z. Ma, K.-i. Otsuyama, H. Asaoku, S. Abroun, X. Zheng, N. Tsuyama, M. Obata, et al.
Dehydroepiandrosterone Can Inhibit the Proliferation of Myeloma Cells and the Interleukin-6 Production of Bone Marrow Mononuclear Cells from Patients with Myeloma
Cancer Res., March 15, 2005; 65(6): 2269 - 2276.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society